Minoxidil
Brand names: Loniten, Regaine (topical)
Minoxidil is a potent oral arterial vasodilator used for severe, treatment-resistant hypertension, usually in combination with other antihypertensives.
Adult dose
Paediatric dose
Dose adjustments
Dosage requirements may be lower in dialysis patients. Minoxidil is removed from the blood by dialysis but its pharmacological action, once established, is not reversed — haemodialysis patients should take minoxidil either after dialysis or at least two hours before it. Patients with renal failure or on haemodialysis may require smaller doses (SPC §4.2/§4.4).
Dose auto-extracted from UK Summary of Product Characteristics (SPC) via the eMC; US FDA prescribing information (openFDA / DailyMed) — cross-check; US labelling may differ from UK — not yet clinician-verified. Always confirm against the product SmPC and your local formulary before prescribing.
SPC §4.2, patients younger than 12 years: use is restricted to children with severe hypertension associated with target organ damage where other treatment has failed. Data are very limited (a few case reports and small studies), especially in infants, and the recommendations are only a rough guide. Starting dose 0.2 mg/kg as a single or divided dose; careful titration in steps of 0.1 to 0.2 mg/kg/day at intervals of at least 3 days is essential; effective dose range 0.25 to 1.0 mg/kg/day; maximum dose 50 mg/day. Treatment of children with minoxidil should only be initiated under the close supervision of a specialist in hospital. Diuretic dosage in children should be proportionally less in relation to weight. Verify against a children's formulary before prescribing.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients
- Phaeochromocytoma (minoxidil may stimulate catecholamine secretion from the tumour through its antihypertensive action)
Side effects
- Hypertrichosis and hair colour changes (hypertrichosis occurs in most patients)
- Fluid retention, oedema; peripheral oedema with or independent of weight gain
- Tachycardia; pericarditis
- Pericardial effusion, cardiac tamponade; pleural effusion
- Abnormal ECG (T-wave changes); leucopoenia, thrombocytopenia
Clinical monograph
How it works
Its active sulphate metabolite opens ATP-sensitive potassium channels in arteriolar smooth muscle, causing relaxation and a fall in peripheral vascular resistance and blood pressure.
Prescribing in practice
- It causes marked fluid retention and reflex tachycardia, so it must almost always be co-prescribed with a diuretic and a beta-blocker (or other rate-controlling agent) to prevent oedema and angina.
- Pericardial effusion, occasionally progressing to tamponade, has been reported and warrants vigilance.
- Hypertrichosis is common and frequently leads to discontinuation, particularly in women; consult the SPC before prescribing.
Monitoring
Monitor blood pressure, heart rate, body weight and fluid status, watching for signs of pericardial effusion.
Counselling the patient
- Warn the patient about increased growth of body and facial hair, which is reversible on stopping.
- Advise reporting rapid weight gain, ankle swelling or breathlessness, and not to stop the medicine abruptly.
Evidence & guidelines
Oral minoxidil is reserved for resistant hypertension under specialist supervision; refer to current prescribing references.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- DOAC Score for Selecting Direct Oral Anticoagulant in Non-Valvular AF · Anticoagulation
- Estimated Fetal Weight (Hadlock) · Fetal Growth
- Salter-Harris Classification of Physeal Fractures · Paediatric Fractures
- Tanner Staging (Sexual Maturity Rating) · Growth & Development
- Fenton Preterm Growth Chart (Gestational Age Correction) · Neonatology
- Acute Heart Failure · ESC 2021 Heart Failure Guidelines; NICE NG106
- NSTEMI / Unstable Angina · ESC 2020 NSTEMI Guidelines; NICE NG185
- New-Onset Atrial Fibrillation · ESC 2020 AF Guidelines; NICE NG196
- Hypertensive Emergency · ESC/ESH 2018 Hypertension Guidelines; NICE NG136
- Bradycardia Management · Resuscitation Council UK ABCDE; ESC 2021 Pacing Guidelines
- Ventricular Tachycardia / Fibrillation · Resuscitation Council UK ACLS; ESC 2022 Ventricular Arrhythmia Guidelines